Competing interests
Chase Cancer
FOX
M.Z.: Institutionally directed research funding from Horizon Therapeutics and Bristol-Myers Squibb; Advisory Board Honorarium from Horizon Therapeutics. K.S.C.: Advisory Board Honorarium from Horizon Therapeutics, institutionally-directed research funding from Bristol-Myers Squibb. E.R.P.: Advisory Board Honorarium from Horizon Therapeutics. H.B.: research support (clinical trials) from BMS, Lilly, Amgen; Advisory Board/Consultant for BMS, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Da Volterra, Puma, BerGenBio, Bayer, Iobiotech; Data and Safety Monitoring Board for University of Pennsylvania (CAR T Program), Takeda, Incyte, Novartis, Springworks; employment at Fox Chase Cancer Center; Scientific Advisory Board for Sonnetbio (stock options), Inspirna (formerly Rgenix, stock options), Nucleai (stock options); honoraria from Amgen, Pfizer, Daiichi, Regeneron; travel support from Amgen, BMS, Merck, Lilly, EMD-Serono, Genentech, Regeneron. The remaining authors declare no competing interests.